Argentina will vaccinate against COVID-19 adolescents between 12 and 17 years of age with risk factors


The Committee for Human Medicines (CHMP) of the European Medicines Agency (EMA) today recommended granting the extension of authorization for emergency use of the Modern Spikevax vaccine against the SARS-CoV-2 virus for the population aged 12 to 17 years, and approval is expected in the next few days. The possibility then opens that, next Tuesday, July 27, the Ministry of Health of the Nation, in consensus with the ministers of the entire country, will expand the scope of the Strategic Vaccination Plan against COVID-19 to adolescents aged 12 and 17 years who have risk factors.
The risk factors that are evaluated to incorporate belong to heart diseases, neurological, kidney, respiratory, obesity, some types of disability and other conditions of vulnerability that will be specified in the meeting next week.

“This recommendation is a very important step that in Argentina will allow us to vaccinate young people between 12 and 17 years old with risk factors in a prioritized manner, which could reach 900,000 people and for which it would require at least 1.8 million doses of this vaccine allowing to ensure complete schedules “, indicated the Minister of Health of the Nation, Carla Vizzotti and added that” this puts in value the decision of the national government to keep in reserve the 3,500,000 Modern vaccines donated by the US ”.

The aforementioned American company presented the Phase III studies and the documentation required to obtain emergency authorization in adolescents both at the EMA and at the United States Food and Drug Administration (FDA). The vaccine has messenger RNA (mRNA), a molecule that carries instructions to produce the Spike protein present in the SARS-CoV-2 that causes the disease COVID-19, with the aim of preparing the body to defend itself in case of being in contact with the virus.

See also  The police are stunned after several strange incidents on Saturday night: - Who did what?

The studies presented to the EMA’s Committee for Human Medicines allowed to raise a binding positive opinion recommending the vaccine in children between 12 and 17 years old, especially in those who are more likely to develop severe forms of the disease since the benefits outweigh the risks.

Last week, during a videoconference with authorities from the national health portfolio and the members of the CoNaIn, representatives of the Moderna laboratory presented the results of their clinical trials, the effectiveness of the vaccine against the new variants, the reinforcement strategy, and the studies carried out in adolescents. In this framework, the members of the commission expressed themselves positively in recommending the use of mRNA platform vaccines in people aged 12 to 17 years, prioritizing those who belong to risk groups.

On the other hand, the Ministry of Health of the Nation confirms the inclusion of Moderna’s messenger RNA platform vaccine in the proof-of-concept study on the evaluation of heterologous vaccine schemes against COVID-19.

.

Leave a Comment